| Name | Ozanimod |
| Description | Ozanimod (RPC-1063) (RPC1063) is a specific oral S1P Receptor 1 modulator. Ozanimod has been used in trials studying the treatment of Crohn's Disease, Ulcerative Colitis, Multiple Sclerosis, and Relapsing Multiple Sclerosis. |
| In vitro | In S1P1R-HEK293T cells, Ozanimod induces sustained S1P1R internalization and degradation. [1] |
| In vivo | In vivo, Ozanimod shows high oral bioavailability and volume of distribution. In a MOG-induced EAE mouse model, Ozanimod (3 mg/kg, p.o.) suppresses Clinicalal symptoms. In a rat TNBS model of inflammatory bowel disease, Ozanimod (1.2 mg/kg, p.o.) inhibits Clinicalal and histological disease scores. In a Na?ve CD4+CD45Rbhi T cell adoptive transfer model, Ozanimod (1.2 mg/kg, p.o.) also significantly reduced disease severity as assessed by measuring the degree of inflammation, gland loss, hyperplasia, neutrophil infiltrate and mucosal thickness. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 41.67 mg/mL (103.03 mM), Sonication is recommended.
10% DMSO+90% Saline : < 4.17 mg/mL (10.31 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
10% DMSO+90% (20% SBE-β-CD in Saline) : < 4.17 mg/mL (10.31 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : < 4.17 mg/mL (10.31 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
Ethanol : 10 mg/mL (24.72 mM), Sonication is recommended.
10% DMSO+90% Corn oil : < 4.17 mg/mL (10.31 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
|
| Keywords | sphingosine 1-phosphate (S1P) | S1PReceptor | S1P5 | S1P1 | S1P receptor subtypes 5 (S1P5) | S1P receptor subtypes 1 (S1P1) | S1P Receptor | RPC1063 | RPC 1063 | Ozanimod | neurosurgery | multiple sclerosis (MS) | Lysophospholipid Receptor | LPLReceptor | LPL Receptor | LPL | Inhibitor | inhibit |
| Inhibitors Related | LX-2931 | Tyloxapol | Sphingosine-1-phosphate | CYM50374 | ASP-4058 | CAY10444 | Ki16198 | Siponimod | CYM5181 | Poloxamer 407 | S1PR1 modulator 1 | MP-A08 |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
United States
